Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Sarah B. Kavanagh currently holds 282,230 shares of Valeant Pharmaceuticals International, Inc. (VRX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Sarah B. Kavanagh has been a net neutral trader of VRX stock. They have purchased $0 and sold $0 worth of shares.
Sarah B. Kavanagh's most recent insider trade was on May 22, 2026, when they sold 45,871 shares at $0.00 per share.
Sarah B. Kavanagh serves as Executive at Valeant Pharmaceuticals International, Inc. (VRX). They have executed 15 insider transactions totaling $0 over their tenure at the company.
Sarah B. Kavanagh holds the position of Executive at Valeant Pharmaceuticals International, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 10 years and currently hold a stake valued at $0.
Sarah B. Kavanagh has shown a balanced trading pattern, with $0 in total purchases and $0 in total sales across all transactions. Their most recent activity indicates a balanced approach to trading.
The largest transaction by Sarah B. Kavanagh was on May 3, 2019, when they purchased $250.0K worth of BHC shares. This transaction involved 10,633 shares at $23.51 per share.
Sarah B. Kavanagh currently owns 282,230 shares of Valeant Pharmaceuticals International, Inc. (VRX), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Sarah B. Kavanagh's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Sarah B. Kavanagh has 15 Form 4 filings on record as an insider at Valeant Pharmaceuticals International, Inc..
Set alerts for Sarah B. Kavanagh and 40,000+ other insiders.